Humana Inc (NYSE:HUM) – Equities research analysts at Leerink Swann upped their FY2018 earnings estimates for shares of Humana in a research note issued to investors on Thursday. Leerink Swann analyst A. Gupte now forecasts that the insurance provider will earn $14.00 per share for the year, up from their previous forecast of $12.25. Leerink Swann has a “Outperform” rating and a $300.00 price objective on the stock. Leerink Swann also issued estimates for Humana’s FY2019 earnings at $17.50 EPS and FY2020 earnings at $19.40 EPS.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $13.19 billion during the quarter, compared to analyst estimates of $13.14 billion. Humana had a net margin of 4.55% and a return on equity of 16.13%. The company’s revenue was up 2.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.34 earnings per share.

A number of other equities analysts have also weighed in on HUM. Zacks Investment Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Credit Suisse Group initiated coverage on shares of Humana in a research report on Thursday, November 2nd. They issued a “neutral” rating and a $256.00 price target for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $242.00 price target (down from $245.00) on shares of Humana in a research report on Thursday, November 9th. Morgan Stanley dropped their price target on shares of Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a research report on Thursday, November 9th. Finally, BMO Capital Markets upped their price target on shares of Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, November 10th. Seven research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Humana currently has a consensus rating of “Buy” and an average target price of $270.47.

Humana (NYSE HUM) traded down $0.64 on Monday, hitting $267.43. 327,430 shares of the company’s stock were exchanged, compared to its average volume of 1,189,920. The company has a market capitalization of $36,767.10, a price-to-earnings ratio of 16.07, a P/E/G ratio of 1.45 and a beta of 0.93. Humana has a fifty-two week low of $203.36 and a fifty-two week high of $293.35. The company has a current ratio of 1.85, a quick ratio of 1.61 and a debt-to-equity ratio of 0.48.

A number of institutional investors have recently added to or reduced their stakes in HUM. Shelton Capital Management purchased a new stake in Humana during the second quarter valued at $287,000. Bank of Nova Scotia raised its stake in Humana by 838.2% during the second quarter. Bank of Nova Scotia now owns 32,632 shares of the insurance provider’s stock valued at $7,852,000 after purchasing an additional 29,154 shares in the last quarter. Scotia Capital Inc. raised its stake in Humana by 4.8% during the second quarter. Scotia Capital Inc. now owns 2,200 shares of the insurance provider’s stock valued at $529,000 after purchasing an additional 100 shares in the last quarter. Sterling Capital Management LLC purchased a new stake in Humana during the second quarter valued at $253,000. Finally, Koch Industries Inc. purchased a new stake in Humana during the second quarter valued at $404,000. 94.13% of the stock is currently owned by institutional investors.

In related news, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $247.89, for a total transaction of $1,748,616.06. Following the completion of the transaction, the senior vice president now owns 11,704 shares in the company, valued at $2,901,304.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares in the company, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,115 shares of company stock valued at $2,501,627. 0.80% of the stock is owned by company insiders.

The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be given a dividend of $0.50 per share. This is a positive change from Humana’s previous quarterly dividend of $0.40. The ex-dividend date is Wednesday, March 28th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.75%. Humana’s dividend payout ratio is currently 9.59%.

Humana announced that its board has initiated a share buyback plan on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

ILLEGAL ACTIVITY NOTICE: “Leerink Swann Weighs in on Humana Inc’s FY2018 Earnings (HUM)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/02/14/leerink-swann-weighs-in-on-humana-incs-fy2018-earnings-hum.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.